Съобщение
Collapse
No announcement yet.
Софарма АД (SFA / SFARM)
Collapse
X
-
Share Price vs. Fair Value
Below are the data sources, inputs and calculation used to determine the intrinsic value for Sopharma AD.An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.Valuation Model 2 Stage Free Cash Flow to Equity Levered Free Cash Flow Extrapolated from most recent financials. See below Discount Rate (Cost of Equity) See below 7.9% Perpetual Growth Rate 5-Year Average of BG Long-Term Govt Bond Rate 3.0% Risk-Free Rate 5-Year Average of BG Long-Term Govt Bond Rate 3.0% Equity Risk Premium S&P Global 6.1% Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.46 Re-levered Beta = 0.33 + [(0.66 * Unlevered beta) * (1 + (1 - tax rate) (Debt/Market Equity))]
= 0.33 + [(0.66 * 0.460) * (1 + (1 - 10.0%) (36.30%))]0.739 Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)0.8 Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.01% + (0.800 * 6.07%)7.87%
Discounted Cash Flow Calculation for BUL:SFA using 2 Stage Free Cash Flow to Equity
The calculations below outline how an intrinsic value for Sopharma AD is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 10 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.2025 3,52 Est @ -71.96% 3,26 2026 1,78 Est @ -49.47% 1,53 2027 1,18 Est @ -33.72% 0,94 2028 0,91 Est @ -22.70% 0,67 2029 0,77 Est @ -14.99% 0,53 2030 0,7 Est @ -9.59% 0,44 2031 0,66 Est @ -5.81% 0,39 2032 0,64 Est @ -3.16% 0,35 2033 0,63 Est @ -1.31% 0,32 2034 0,63 Est @ -0.02% 0,3 Present value of next 10 years cash flows BGN8,73 Terminal Value FCF2034 × (1 + g) ÷ (Discount Rate – g)
= BGN0,63 x (1 + 3.01%) ÷ (7.87% - 3.01% )BGN13,36 Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
BGN13 ÷ (1 + 7.87%)10BGN6,27 Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= BGN9 + BGN6BGN14,99 Equity Value per Share
(BGN)= Total value / Shares Outstanding
= BGN15 / 166BGN0,09 Learn more about our DCF calculations in Simply Wall St’s analysis modelValue per share (BGN) From above. BGN0.090 Current discount Discount to share price of BGN6.02
= (BGN0.090 - BGN6.02) / BGN0.090-6,554.2%
Много интересна оценка ;-)
Коментар
-
Първоначално изпратено от angelgarba Разгледай мнениеНещо се пече тука
Дивидента трапна бая масовик тук.Няма излизане 5г сега
- 1 like
Коментар
-
Първоначално изпратено от tony1975 Разгледай мнениедали не са се отказали от сделката, щом предлагат дивидент?
Коментар
-
дали не са се отказали от сделката, щом предлагат дивидент?Sopharma proposed BGN 0.075 gross DPS for H1’24; shareholders to vote on new buyback procedure (POSITIVE) Sopharma’s Board of Directors filed a GSM invitation for 25 October 2024, where shareholders will vote on distributing BGN 0.075 gross DPS from the H1’24 financial result. The total amount to be distributed should be c. BGN 12.4m (165.7m outstanding shares). The payout ratio stands at 55.8% while the annual dividend yield when accounting for the BGN 0.09 dividend voted in June comes to 2.8%.
The shareholders would also vote on new buyback procedure under the following conditions: not more than 3% of the capital per calendar year at a minimum price per share of BGN 1 and a maximum price per share of BGN 7.00 with 18 months term of the procedure. Note that the current buyback procedure has an upper price limit of BGN 6.50 while Sopharma has treasury stock of 7.46% of the capital.
Source: Sopharma; Commercial Registry; FFBH
- 2 Харесвания
Коментар
-
Първоначално изпратено от inta53 Разгледай мнениеЧичо ви е пуснал стотинките...Мнението ми не представлява съвет за покупко-продажба на акции, облигации и други видове ценни книжа
Коментар
-
Achieve Life Sciences, Inc
Recent Highlights- The FDA granted Breakthrough Therapy designation for cytisinicline treatment of nicotine e-cigarette, or vaping, cessation
- Completed refinancing and extended the maturity date of outstanding term loans with Silicon Valley Bank (SVB)
- Joined the U.S. Russell 3000® and Russell Microcap® Indexes
- Initiated ORCA-OL clinical trial evaluating long-term exposure of cytisinicline in people who smoke or use nicotine e-cigarettes
- Presented data from cytisinicline ORCA-V1 program at Society of General Internal Medicine (SGIM) Annual Meeting
“We are extremely proud of the significant milestones we have accomplished over the last few months, including the granting of Breakthrough Therapy designation for cytisinicline for vaping cessation, which highlights the urgent need for an effective treatment to help the millions of people who are battling nicotine vape addiction,” stated John Bencich, Chief Executive Officer of Achieve. “Additionally, we initiated and are making great progress in the ORCA-OL trial evaluating long-term cytisinicline exposure moving us closer to our expected NDA filing in the first half of 2025.”
- 1 like
Коментар
-
Първоначално изпратено от Дядо Коледа Разгледай мнение
Телекомплект е синджир марка на Софарма, но косвено
надежда някъде нещо да поскъпне от синджирите, да го махнат и да идат на друг който не е поскъпнал. Нещо като "тука има, тука нема"
- 1 like
Коментар
-
Първоначално изпратено от MrProfit Разгледай мнение
Най-вероятно ги е купил несвързан акционер с над 5% ("Телекомплект инвест" АД).
- 1 like
Коментар
-
Първоначално изпратено от MrProfit Разгледай мнение
Най-вероятно ги е купил несвързан акционер с над 5% ("Телекомплект инвест" АД).
Коментар
-
Първоначално изпратено от sunny Разгледай мнениеНе разбирам къде потъна един пакет от 710 к обратно изкупени акции, продадени от Софарма на 25 юни. Не намирам съобщения в ЕксТри, а ФФ не се е увеличил толкова много...
Коментар
Коментар